KEYMED BIOSCIENCES -0001
Research KEYMED BIOSCIENCES -0001 (64Z) on Bullrun: market cap EUR 2.47B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker64Z
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 2.47B
- Financial periodFY2025
- RevenueCNY 716.31M
- Revenue growth67.3%
- Net income-CNY 522.64M
- Free cash flow-CNY 1.05B
- Gross margin87.7%
Valuation Snapshot
latest market cap is EUR 2.47B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 716.31M | -CNY 522.64M | -CNY 1.05B | 87.7% | -1.91 | CNY 503.35M | CNY 788.54M | CNY 2.77B |
| FY2024 | CNY 428.12M | -CNY 515.24M | -CNY 1.00B | 97.2% | -1.97 | CNY 418.41M | CNY 753.24M | CNY 2.47B |
| FY2023 | CNY 354.10M | -CNY 359.36M | -CNY 686.23M | 89.6% | -1.37 | CNY 851.03M | CNY 418.71M | CNY 2.99B |
| FY2022 | CNY 100.06M | -CNY 308.12M | -CNY 681.48M | 97.4% | -1.18 | CNY 604.07M | CNY 121.97M | CNY 3.34B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 2.47B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About KEYMED BIOSCIENCES -0001
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The company develops Kangyueda for the treatment of moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis; CMG901/AZD0901, an antibody drug conjugate for treatment of advanced solid tumors;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is KEYMED BIOSCIENCES -0001's market cap?
KEYMED BIOSCIENCES -0001's market capitalization is EUR 2.47B.
What does KEYMED BIOSCIENCES -0001 do?
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom.